Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1951 to 1965 of 8900 results

  1. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

    In development Reference number: GID-TA11379 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. UX111 for treating mucopolysaccharidosis type IIIA [ID6540]

    Awaiting development Reference number: GID-TA11701 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Bladder cancer: diagnosis and management (update)

    In development Reference number: GID-NG10452 Expected publication date: TBC

    NICE guideline
    In development

  4. Prostate cancer: diagnosis and management (update)

    In development Reference number: GID-NG10451 Expected publication date: TBC

    NICE guideline
    In development

  5. Fenebrutinib for treating relapsing multiple sclerosis [ID6577]

    Awaiting development Reference number: GID-TA11775 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Norucholic acid for treating primary sclerosing cholangitis [ID6583]

    Awaiting development Reference number: GID-TA11782 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]

    Awaiting development Reference number: GID-TA11744 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]

    Awaiting development Reference number: GID-TA11743 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]

    Awaiting development Reference number: GID-TA11667 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    In development Reference number: GID-TA11535 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Ruxolitinib for Prurigo Nodularis [ID6571]

    In development Reference number: GID-TA11760 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]

    Awaiting development Reference number: GID-TA11720 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Elinzanetant for Vasomotor symptoms [ID6544]

    Awaiting development Reference number: GID-TA11784 Expected publication date:  21 July 2027

    Technology appraisal guidance
    Awaiting development

  14. Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]

    Awaiting development Reference number: GID-TA11721 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]

    Awaiting development Reference number: GID-TA11692 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development